hyperthyroidism

in review 5 min read Updated 2026-11-19
hyperthyroidism

Split thyrotoxicosis into high radioactive iodine uptake (RAIU) (overproduction: Graves, TMNG, toxic adenoma — treat with antithyroid drugs, RAI, or surgery) vs low RAIU (destructive release or exogenous hormone — antithyroid drugs do not work). Ophthalmopathy = Graves disease regardless of RAIU. First-line antithyroid drug is methimazole (except first trimester of pregnancy and thyroid storm → PTU).

do not miss

Thyroid storm (fever, delirium/agitation, tachycardia/AF, HF, GI/jaundice) is a clinical diagnosis requiring immediate ICU management before confirmatory labs → thyroid emergencies. Any patient on antithyroid drugs with fever or sore throat needs an urgent CBC for agranulocytosis (ANC <0.5 × 10⁹/L) and immediate drug cessation.


diagnostic approach — high vs low RAIU

Confirm suppressed TSH with elevated free T4 and/or free T3 (T3-toxicosis occurs early in Graves and toxic nodules). Biotin (>30 µg/day; often 5–10 mg OTC for hair/nails) interferes with streptavidin-biotin immunoassays → falsely low TSH and falsely high free T4/T3 mimicking Graves; hold biotin ≥72 hours before retesting.

  • Clinical Graves (diffuse goitre + orbitopathy or pretibial myxoedema) or positive TRAb: no RAIU needed — diagnosis is established.
  • Uncertain aetiology: order TRAb or ¹²³I uptake and scan (RAIU) (never in pregnancy/breastfeeding; colour-flow Doppler US is an alternative).
RAIU patterncauseskey distinguishing features
high / normal — diffuseGraves diseaseTRAb+, diffuse bruit/goitre, orbitopathy, dermopathy
high / normal — patchy / focalTMNG (patchy) · toxic adenoma (single hot nodule, suppressed remainder)older adults, no orbitopathy; do not FNA a hot nodule
low (<5%)subacute (de Quervain) thyroiditispainful tender thyroid, ↑ ESR/CRP, post-viral
low (<5%)painless / postpartum / ICI thyroiditispainless; triphasic (hyper → hypo → recovery); ICI often progresses to permanent hypothyroidism
low (<5%)amiodarone-induced (AIT)Type 1 (iodine-induced synthesis) vs Type 2 (destructive); RAIU often falsely low in both
low (<5%)factitious / exogenous · struma ovariiexogenous → low/undetectable thyroglobulin; struma ovarii → high thyroglobulin + pelvic uptake
  • Falsely low RAIU: recent iodinated CT contrast, amiodarone, kelp/iodine supplements, or active thionamide use. Ophthalmopathy still confirms Graves even if RAIU is suppressed.

symptom control and definitive management

  • β-blockers for all symptomatic patients (especially older adults, resting HR >90 bpm, or CVD): propranolol (also inhibits T4 → T3 conversion at high doses), atenolol, or metoprolol.
  • Subclinical hyperthyroidism (low TSH, normal free T4/T3): treat if TSH <0.1 mU/L and age ≥65, osteoporosis, heart disease/atrial fibrillation, or symptoms (consider if TSH 0.1–0.4 with same risks).

Graves disease — three options

modalityrole & timingkey contraindications / caveats
antithyroid drugs (methimazole first-line)12–18 months; ~50% remission (higher if small goitre, falling TRAb); takes 4–6 weeks for full effectPTU only for T1 pregnancy, thyroid storm, or minor MMZ intolerance. Major reaction (agranulocytosis, transaminases >3× ULN, ANCA vasculitis) → stop permanently, never switch
radioactive iodine (¹³¹I)single oral ablative dose; definitive hypothyroidism in >80% (lifelong LT4)contraindicated in pregnancy, breastfeeding, moderate–severe active orbitopathy, or suspected thyroid cancer. Delay pregnancy 6 months. Hold methimazole 2–3 days before RAI. Cover mild active GO with oral prednisone
total thyroidectomyrapid definitive cure (large compressive goitre, coexisting cancer, severe GO, pregnancy refractory to ATDs, desire for pregnancy <6 months)render euthyroid first; give SSKI or Lugol’s iodine × 10 days pre-op (↓ vascularity/blood loss); watch for hypoparathyroidism and RLN injury

TMNG and toxic adenoma

  • Do not remit spontaneously → definitive RAI or surgery (surgery preferred for compressive goitre, suspected malignancy, or rapid control; lifelong low-dose methimazole is an option in frail older adults).

thyroiditis (low-RAIU)

  • Thionamides are ineffective (preformed hormone leak, no excess synthesis). Treat symptoms with β-blockers.
  • Subacute (painful): NSAIDs first-line; prednisone if severe pain or refractory.
  • ICI-induced thyroiditis: β-blocker during thyrotoxic phase; monitor TSH/FT4 every 2–4 weeks because most transition rapidly to permanent hypothyroidism (check morning cortisol before starting LT4 if hypophysitis is possible → immune checkpoint inhibitor toxicity).

amiodarone-induced thyrotoxicosis (AIT)

featureType 1 AIT (Jod–Basedow)Type 2 AIT (destructive thyroiditis)
mechanismexcess iodine synthesis (underlying Graves or nodular goitre)direct follicular cell toxicity (normal gland)
colour-flow Doppler US↑ vascularity (often unreliable alone)absent / ↓ vascularity
first-line therapymethimazole (often high dose, 30–40 mg/day)prednisone (e.g. 30–40 mg/day with taper)
  • Unstable or uncertain subtype (frequent overlap): start both methimazole and prednisone together (ATA 2016 strong recommendation).
  • Stopping amiodarone: decide jointly with cardiology — its tissue half-life lasts months and abrupt withdrawal removes cardiac T3 antagonism, risking fatal arrhythmias.

Graves orbitopathy (EUGOGO 2021)

Assess activity (Clinical Activity Score CAS ≥3/7 = active: retrobulbar pain, gaze pain, lid/conjunctival redness, lid/caruncle swelling, chemosis) and severity (mild, moderate–severe, sight-threatening).

  • All patients: strict smoking cessation (strongest modifiable risk factor for progression and poor treatment response), restore euthyroidism promptly, avoid post-RAI hypothyroidism, and start preservative-free lubricating eye drops/gels.
  • Mild active GO: local lubricants + selenium (sodium selenite 200 µg daily × 6 months); avoid RAI or cover with prednisone.
  • Moderate–severe active GO: first-line = IV methylprednisolone (cumulative 4.5 g over 12 weekly infusions) + mycophenolate (sodium 720 mg/day or MMF 1 g/day × 24 weeks); for more severe cases (constant/inconstant diplopia, severe proptosis/soft-tissue signs), use higher-dose IV methylprednisolone 7.5 g monotherapy (cumulative safety limit 8.0 g/cycle — not combined with mycophenolate). Second-line options: repeat IV steroids, orbital radiotherapy, rituximab, tocilizumab, or teprotumumab (availability in Canada limited).
  • Sight-threatening GO (dysthyroid optic neuropathy or corneal breakdown): urgent high-dose IV methylprednisolone (500–1,000 mg daily × 3 days or alternate days) → urgent orbital decompression if poor response within 1–2 weeks.
  • Rehabilitative surgery (decompression → strabismus → eyelid): only once inactive for ≥6 months.

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

Suggest a correction hyperthyroidism